Ann: R&D Update - Molecular Medicine ASO Project, page-9

Is anyone else a little worried that they may be attempting to diversify too much? I often find with these types of companies that it is best to focus on one core product with the greatest potential. Yes, the greater diversification takes some risk off the table but is this really necessary now with the significant and likely potential of hepafat following the FDA approval? The way I see it considering the size of this market the best value can be delivered to shareholders through focusing on the marketing of hepafat while we have a first mover advantage. After we have developed a solid reputation then diversification should be considered but I feel they may be putting far too much on the plate all at once. Of course, I am still doing my own research so please let me know if am missing something here. Cheers